ARA-290 Mechanism: Innate Repair Receptor Research Findings

ARA-290, also referred to as cibinetide, is a synthetic peptide derived from the tertiary structure of erythropoietin (EPO) and characterised in published work through its interaction with the innate repair receptor (IRR). It is described as non-hematopoietic, meaning the literature reports no affinity for the receptor complex associated with red blood cell formation. This page summarises the receptor pathway and the research endpoints reported in laboratory work.

The innate repair receptor

The IRR is described as a heterocomplex of the erythropoietin receptor (EPOR) and the common beta-receptor subunit (CD131 / βcR). Where EPO binds the homodimeric EPOR, IRR engagement is reported as occurring under conditions of metabolic stress or tissue injury.

ARA-290 is described as a high-affinity ligand for the IRR. Downstream measurements in the literature include reduced pro-inflammatory cytokine levels such as TNF-α and IL-6, JAK2/STAT and PI3K/Akt signalling readouts, mitochondrial membrane-potential measures, and shifts in macrophage phenotype markers from M1 to M2 profiles. This receptor-mediated framing separates it from redox-focused compounds such as Glutathione, which are studied through antioxidant chemistry instead.

Neuroinflammation and small-fibre endpoints

A large share of ARA-290 literature reports small-fibre measurements, characterised by degeneration of unmyelinated C-fibres and lightly myelinated Aδ-fibres in the models examined. Corneal nerve fibre density (CNFD) appears frequently as a quantitative readout.

Randomised, placebo-controlled study designs report changes in small nerve fibre measurements alongside inflammatory-marker readouts. NLRP3 inflammasome activity within nervous tissue is one of the mechanisms discussed in that literature. This receptor-signalling profile is often compared in laboratory settings with compounds such as BPC-157, which is characterised through angiogenic and growth-factor readouts rather than IRR engagement.

Metabolic and cardiovascular research endpoints

Laboratory work has extended ARA-290 measurement into metabolic and cardiovascular models. Type 2 diabetes models report glucose-handling and insulin-sensitivity readouts, discussed in relation to measured inflammatory signalling within adipose and pancreatic tissue.

Cardiovascular models report tissue-protection measurements following ischaemia-reperfusion challenge, including infarct-area quantification and endothelial-integrity readouts. Reported data describe these measurements without accompanying increases in haematocrit, consistent with the non-hematopoietic characterisation. In broader cellular-pathway research, ARA-290 is sometimes examined alongside NAD+ for mitochondrial-function endpoints.

Methodological context

ARA-290 study design is shaped by the peptide's short circulating half-life. Published designs commonly run measurement windows of several weeks to observe changes in nerve-fibre density or inflammatory markers, and emphasise consistent timing because IRR engagement is reported as transient while downstream signalling persists longer.

The literature also notes that ARA-290 is not reported to alter endogenous hormone output in the models examined, which is why it is used as a comparatively isolated probe for IRR-mediated inflammatory signalling. Researchers sourcing material for these designs can review specifications and batch verification on the ARA-290 catalog page.

Material handling

ARA-290 is supplied as lyophilized powder for laboratory use and is sensitive to temperature and light. Material should be stored refrigerated, dry, and protected from light, following the documentation supplied with the received batch. Batch identifiers can be checked through the public lookup.

Limitations

Short circulating half-life remains the most frequently cited limitation, since the peptide is rapidly degraded by proteases while downstream signalling persists — complicating exposure-response modelling.

Reported findings are concentrated in a narrow set of models, and extension to more complex immune models is not established. Because IRR expression is reported as stress-dependent, measurable activity in unstressed tissue is negligible, which limits baseline comparisons. Longer-duration characterisation of off-target signalling remains an open research question.

Frequently asked questions

Q: What is the innate repair receptor? It is described in the literature as a heteromer of the EPO receptor and the CD131 common beta subunit, reported as expressed under tissue stress.

Q: Why is ARA-290 called non-hematopoietic? Because published work reports no binding to the homodimeric EPO receptor associated with red blood cell formation.

Q: How does ARA-290 differ from broad anti-inflammatory agents? Published characterisation is receptor-specific: measurements centre on IRR signalling rather than broad enzyme or immune-pathway inhibition.

Q: How should lyophilized material be stored? Refrigerated, dry, and protected from light, following the batch documentation supplied with the received unit.

Research Use Only. This content is intended for laboratory and research purposes only. Not for human consumption, diagnosis, or treatment.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.